Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Tang

Showing results (171-180 of 221) with videos related to

Pageof 23
Sort By:
Future Oncology (London, England)|September 11, 2024
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative reviewAugust C Anderson, Joel Ho, Evan T Hall, et al.
Cancer|February 17, 2021
Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancerDario Pasalic, Daniel A Barocas, Li-Ching Huang, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Brachytherapy|March 2, 2025
Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancerOsama Mohamad, Zakaria El Kouzi, Ramez Kouzy, et al.
Cell|September 4, 2010
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaMark P Chao, Ash A Alizadeh, Chad Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I ClinicDenis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Cancers|December 17, 2024
Upper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla Magnetic Resonance Imaging-Guided Linear Accelerator: Workflow and Physics ConsiderationsYao Zhao, Adrian Cozma, Yao Ding, et al.
Journal of Neurosurgery. Spine|June 14, 2024
Stereotactic radiosurgery for prostate cancer spine metastases: local control and fracture risk using a simultaneous integrated boost approachThomas H Beckham, Michael K Rooney, Gizem Cifter, et al.
The Lancet. Oncology|June 29, 2026
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trialGiulio Francolini, Vanessa Di Cataldo, Saverio Caini, et al.
Pageof 23

Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
Future Oncology (London, England)|September 11, 2024
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative reviewAugust C Anderson, Joel Ho, Evan T Hall, et al.
Cancer|February 17, 2021
Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancerDario Pasalic, Daniel A Barocas, Li-Ching Huang, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
Brachytherapy|March 2, 2025
Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancerOsama Mohamad, Zakaria El Kouzi, Ramez Kouzy, et al.
Cell|September 4, 2010
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaMark P Chao, Ash A Alizadeh, Chad Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I ClinicDenis L F Jardim, Chad Tang, Debora De Melo Gagliato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Cancers|December 17, 2024
Upper Urinary Tract Stereotactic Body Radiotherapy Using a 1.5 Tesla Magnetic Resonance Imaging-Guided Linear Accelerator: Workflow and Physics ConsiderationsYao Zhao, Adrian Cozma, Yao Ding, et al.
Journal of Neurosurgery. Spine|June 14, 2024
Stereotactic radiosurgery for prostate cancer spine metastases: local control and fracture risk using a simultaneous integrated boost approachThomas H Beckham, Michael K Rooney, Gizem Cifter, et al.
The Lancet. Oncology|June 29, 2026
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trialGiulio Francolini, Vanessa Di Cataldo, Saverio Caini, et al.
Pageof 23